BostonGene Highlights AI-Powered Oncology Research at ASCO 2026
WALTHAM, Mass. | May 28, 2026 BostonGene announced that nine abstracts have been accepted for presentation at the 2026...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
WALTHAM, Mass. | May 28, 2026 BostonGene announced that nine abstracts have been accepted for presentation at the 2026...
TARRYTOWN, N.Y., May 21, 2026 Sapience Therapeutics has announced encouraging updated clinical data from its ongoing Phase 2 trial...
San Diego, California, USA, April 6, 2026 FDA Engagement Signals Registrational Pathway Progress In a key development for oncolytic...
DENVER, USA – March 18, 2026 TriSalus Life Sciences has announced new preclinical findings demonstrating that its Pressure-Enabled Drug...
SUZHOU, China, Feb. 15, 2026 — CStone Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Investigational...
SYDNEY, Dec. 10, 2025 — Kazia Therapeutics Limited (NASDAQ: KZIA) unveiled compelling clinical and translational data highlighting the ability...
October 14, 2025 | Düsseldorf, Germany — Abalos Therapeutics announced the publication of preclinical proof-of-concept data in Cell Reports...
BRONX, NY, Oct. 3, 2025 — Researchers at Montefiore Einstein and Albert Einstein College of Medicine reveal that glioblastoma...
